Evidence map›Paper›PMID 28594877›Full record

ArticlePloS one2017

An indicator cell assay for blood-based diagnostics.

Samuel A Danziger, Leslie R Miller, Karanbir Singh, G Adam Whitney, Elaine R Peskind, Ge Li, Robert J Lipshutz, John D Aitchison, Jennifer J Smith

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Samuel A DanzigerInstitute for Systems Biology, Seattle, WA, United States of America.
Leslie R MillerInstitute for Systems Biology, Seattle, WA, United States of America.
Karanbir SinghInstitute for Systems Biology, Seattle, WA, United States of America.
G Adam WhitneyPreCyte Inc., Seattle, WA, United States of America.
Elaine R PeskindNorthwest Network (VISN-20) Mental Illness, Research, Education, and Clinical Center (MIRECC), VA Puget Sound, Seattle, WA, United States of America.
Ge LiDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, United States of America.
Robert J LipshutzInstitute for Systems Biology, Seattle, WA, United States of America.
John D AitchisonInstitute for Systems Biology, Seattle, WA, United States of America.
Jennifer J SmithInstitute for Systems Biology, Seattle, WA, United States of America.ORCID http://orcid.org/0000-0001-5780-7209

Funding

THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
Quantitative Systems BiologyP50GM076547 · NIGMS · INSTITUTE FOR SYSTEMS BIOLOGY · PI DUDLEY, AIMEE M · 2006 to 2016
$30.6M
Udall Center Director's meeting poster awardP50NS062684 · NINDS · UNIVERSITY OF WASHINGTON · PI MONTINE, THOMAS J · 2009 to 2020
$18.3M
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimers DiseaseR44AG051282 · NIA · PRECYTE, INC. · PI SMITH, JENNIFER JOY · 2015 to 2020
$5.0M
Development of an Indicator Cell Assay for blood-based diagnosis of lung cancerR43CA203455 · NCI · PRECYTE, INC. · PI SMITH, JENNIFER JOY · 2016 to 2016
$300k
NCI NIH HHS R43 CA203455NIA NIH HHS P50 AG005136NIA NIH HHS R44 AG051282NIGMS NIH HHS P50 GM076547NINDS NIH HHS P50 NS062684
6 · The paper itself

Abstract

We have established proof of principle for the Indicator Cell Assay Platform™ (iCAP™), a broadly applicable tool for blood-based diagnostics that uses specifically-selected, standardized cells as biosensors, relying on their innate ability to integrate and respond to diverse signals present in patients' blood. To develop an assay, indicator cells are exposed in vitro to serum from case or control subjects and their global differential response patterns are used to train reliable, disease classifiers based on a small number of features. In a feasibility study, the iCAP detected pre-symptomatic disease in a murine model of amyotrophic lateral sclerosis (ALS) with 94% accuracy (p-Value = 3.81E-6) and correctly identified samples from a murine Huntington's disease model as non-carriers of ALS. Beyond the mouse model, in a preliminary human disease study, the iCAP detected early stage Alzheimer's disease with 72% cross-validated accuracy (p-Value = 3.10E-3). For both assays, iCAP features were enriched for disease-related genes, supporting the assay's relevance for disease research.

Indexed as

Alzheimer DiseaseAmyotrophic Lateral SclerosisAnimalsBiological AssayDisease Models, AnimalEmbryoid BodiesHumansMaleMiceSensitivity and SpecificitySuperoxide Dismutase-1SOD1 protein, humanSuperoxide Dismutase-1

Identifiers

PMID28594877
PMCPMC5464608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.